Search results for "Dose-Response Relationship"

showing 10 items of 1408 documents

Effect of loperamide on jejunal electrolyte and water transport, prostaglandin E 2-induced secretion and intestinal transit time in man

1991

Jejunal perfusion was performed in 12 healthy volunteers to evaluate the dose dependent effects of loperamide on intestinal absorption, stimulated secretion and transit. In 6 volunteers intestinal perfusion of the jejunal segment with isotonic NaCl solution was followed by addition of loperamide in increasing doses (2–8 mg·l−1). The volunteers were pretreated with 1 mg·l−1 prostaglandin E2 (PgE2) in the perfusate before addition of 4 mg·l−1 loperamide. Phenolsulphonphtalein (PSP) boluses (2 ml) were given to measure mean transit time (MTT). Loperamide 2 mg·l−1 converted the minor secretion after perfusion with the standard solution (water −1.45 ml·min−1, Na −0.09 and Cl −0.04 mmol·min−1) to…

AdultDiarrheaMalemedicine.medical_specialtyLoperamideAdolescentAbsorption (skin)LoperamideDinoprostoneIntestinal absorptionJejunumChloridesInternal medicinemedicineHumansPharmacology (medical)Prostaglandin E2Gastrointestinal TransitPharmacologyWater transportDose-Response Relationship DrugChemistrySodiumBiological TransportGeneral MedicineWater-Electrolyte BalanceJejunumEndocrinologymedicine.anatomical_structureIntestinal AbsorptionMechanism of actionmedicine.symptomPerfusionmedicine.drugEuropean Journal of Clinical Pharmacology
researchProduct

Cetuximab plus cisplatin–5-fluorouracil versus cisplatin–5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a ra…

2009

Abstract Background This study assessed the activity of the mAb cetuximab in combination with cisplatin and 5-fluorouracil (5-FU) in advanced esophageal squamous cell carcinoma. Patients and methods For a maximum of six 29-day cycles, patients received cisplatin 100 mg/m2, day 1, plus 5-FU 1000 mg/m2, days 1–5 (CF), either alone or in combination with cetuximab (CET–CF; 400 mg/m2 initial dose followed by 250 mg/m2 weekly thereafter). The primary end point was tumor response. Tumor material was obtained for analysis of KRAS mutation status. Results Sixty-two eligible patients were included, 32 receiving CET–CF and 30 CF. Cetuximab did not exacerbate grade 3/4 toxicity, except for rash (6% ve…

AdultDiarrheaMalemedicine.medical_specialtyNeutropeniaTime FactorsEsophageal NeoplasmsCetuximabPhases of clinical researchKaplan-Meier EstimateAntibodies Monoclonal Humanizedmedicine.disease_causeGastroenterologyDisease-Free SurvivalInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProgression-free survivalAgedCross-Over StudiesDose-Response Relationship DrugCetuximabbusiness.industryAntibodies MonoclonalNauseaHematologyMiddle AgedCombined Modality TherapySurvival AnalysisChemotherapy regimenSurgeryTreatment OutcomeOncologyEpidermoid carcinomaFluorouracilResponse Evaluation Criteria in Solid TumorsCarcinoma Squamous CellFemaleFluorouracilKRASCisplatinbusinessFollow-Up Studiesmedicine.drugAnnals of Oncology
researchProduct

Once-daily tiotropium Respimat® 5 μg is an efficacious 24-h bronchodilator in adults with symptomatic asthma

2015

SummaryIntroductionOnce-daily tiotropium Respimat® 5 μg is an efficacious add-on therapy to inhaled corticosteroids (ICS) with or without long-acting β2-agonists in patients with symptomatic asthma. The objective of this study was to investigate whether the dosing regimen of tiotropium (once- versus twice-daily), delivered via the Respimat® SoftMist™ inhaler, affected 24-h bronchodilator efficacy and safety versus placebo Respimat® in patients with asthma who were symptomatic despite medium-dose ICS therapy.MethodsA randomised, double-blind, placebo-controlled, crossover study with 4-week treatment periods of tiotropium 5 μg (once-daily, evening) and 2.5 μg (twice-daily, morning and evening…

AdultEstoniaMalePulmonary and Respiratory MedicineVital capacityRespimatEveningAdolescentmedicine.drug_classPlaceboDouble-Blind MethodRisk FactorsAnticholinergic drugForced Expiratory VolumeGermanyBronchodilatorAdministration InhalationmedicineHumansDosingDosing regimenTiotropium BromideAgedCzech RepublicAsthmaLong-acting bronchodilatorCross-Over StudiesDose-Response Relationship Drugbusiness.industryTiotropiumInhalerMiddle Agedmedicine.diseaseLatviaAsthmaBronchodilator Agentsrespiratory tract diseasesTreatment OutcomeBronchodilator efficacyAustriaAnesthesiaFemalebusinessRespiratory Medicine
researchProduct

Treatment of acute rejection of cadaveric renal allografts with rabbit antithymocyte globulin.

1982

In a prospective randomized single-blind trial, we compared the effectiveness of rabbit antithymocyte globulin (RATG) in the treatment of acute renal graft rejection with the results of treatment by high oral doses of prednisone. Twenty recipients of cadaveric kidneys were included in each group. In the RATG group, the prednisone dose was not increased and a dose-by-rosette protocol was used to keep T cell levels between 50 and 150/mm3. In this group 15 of the 20 patients responded to the treatment. One of these patients lost her kidney afterward because of a technical failure. In five patients rejection was irreversible despite a subsequent course of high-dose prednisone orally. In the pre…

AdultGraft RejectionMaleTransplantationmedicine.medical_specialtyTime FactorsDose-Response Relationship Drugbusiness.industryT-LymphocytesRenal graftKidney TransplantationSurgeryRabbit antithymocyte globulinLeukocyte CountPrednisoneMedicineHumansPrednisoneFemaleProspective StudiesbusinessCadaveric spasmmedicine.drugAntilymphocyte SerumTransplantation
researchProduct

Treatment of Vaginal Trichomoniasis with a Single Dose of Tinidazole

1974

SummaryTwenty-two patients with proven vaginal trichomoniasis were treated with a single dose of 2 g. tinidazole. Twenty-one patients were cured, at both the early and the late follow-up visits. No side-effects were noted and no abnormalities of the clinical laboratory parameters were found in the trial. A historical comparison with published works was carried out and the results compared favourably with those found in the literature for tinidazole as well as for other agents used in a similar fashion.

AdultGynecologymedicine.medical_specialtyDose-Response Relationship Drugbusiness.industryVaginal trichomoniasisAdministration OralAntitrichomonal AgentsGeneral MedicineMiddle AgedTrichomonal VaginitisDermatologyTinidazoleAntitrichomonal agentchemistry.chemical_compoundchemistryNitroimidazolesmedicineHumansFemaleTrichomonas Vaginitisbusinessmedicine.drugCurrent Medical Research and Opinion
researchProduct

Effect of cordycepin on interleukin-10 production of human peripheral blood mononuclear cells

2002

Therapeutic options for controlling autoimmune diseases are still very limited. Interleukin-10 has been reported to be a promising approach to therapeutic intervention. In the search for a drug which results in the selective upregulation of interleukin-10, we investigated the immunoregulative effects of cordycepin. We have measured interleukin-10 and interleukin-2 secretion of human peripheral blood mononuclear cells that were incubated with cordycepin and assessed the influence of cordycepin on the expression of interleukin-10 mRNA, the proliferative response and the expression of surface markers on T lymphocytes. In addition, the subsets of interleukin-10-secreting cells, the influence of…

AdultInterleukin 2T-Lymphocytesmedicine.medical_treatmentPharmacologyBiologyLymphocyte ActivationPeripheral blood mononuclear cellchemistry.chemical_compoundAdjuvants ImmunologicAntigens CDmedicineHumansRNA MessengerIL-2 receptorCells CulturedPharmacologyDeoxyadenosinesDose-Response Relationship DrugCordycepinMonocyteInterleukinFlow CytometryInterleukin-10Up-RegulationInterleukin 10medicine.anatomical_structureCytokinechemistryImmunologyLeukocytes MononuclearInterleukin-2Cell Divisionmedicine.drugEuropean Journal of Pharmacology
researchProduct

Evidence that the interaction between circulating IgA and fibronectin is a normal process enhanced in primary IgA nephropathy

1991

A solid-phase ELISA was set up to measure the direct binding capacity (BC) of different, commercially available, purified human IgA preparations to plates coated with human fibronectin (FN). It was found that secretory, polymeric, and, to a much lesser extent, monomeric IgA exhibited elevated FN-BC as compared to their BC to plates coated with bovine serum albumin. This binding was specific since not observed with human IgG or IgM antibodies. In addition, we noted that this interaction was dose dependent, Ca2+ dependent, saturable, and not covalent, was inhibited by soluble FN, but not by a prior incubation of FN-coated plates with anti-human fibronectin antibodies, and appeared to involve …

AdultLiver CirrhosisMaleImmunoglobulin Amedicine.medical_specialtyHot TemperatureAdolescentImmunologyEnzyme-Linked Immunosorbent AssayAntigen-Antibody ComplexPathogenesisAntibody SpecificityInternal medicinemedicineHumansImmunology and AllergyBovine serum albuminEdetic AcidDose-Response Relationship DrugbiologyChemistryGlomerulonephritis IGAGlomerulonephritisMiddle Agedmedicine.diseaseFibronectinsFibronectinsImmunoglobulin AFibronectinDose–response relationshipEndocrinologyChromatography Gelbiology.proteinCalciumFemaleAntibody
researchProduct

Clinical Trial: High-dose furosemide plus small-volume hypertonic saline solutions vs. repeated paracentesis as treatment of refractory ascites.

2009

Summary Background  In patients with cirrhosis, ascites is defined as refractory when it cannot be mobilized or recurs early in standard diuretic therapy. Aim  To compare the safety and efficacy of intravenous high-dose furosemide + hypertonic saline solutions (HSS) with repeated paracentesis in patients with cirrhosis and refractory ascites. Patients and methods  Eighty-four subjects (59/25 M/F) with cirrhosis, mostly of viral aetiology, admitted for refractory ascites, were randomly assigned to receive furosemide (250–1000 mg/bid i.v.) plus HSS (150 mL H2O with NaCl 1.4–4.6% or 239–187 mEq/L) (60 patients, Group A) or to repeated paracentesis and a standard diuretic schedule (24 patients,…

AdultLiver CirrhosisMalemedicine.medical_specialtyCirrhosismedicine.medical_treatmentPilot ProjectsRefractoryFurosemideAscitesmedicineParacentesishypertonic saline solutionHumansParacentesisPharmacology (medical)DiureticsAgedAged 80 and overSaline Solution HypertonicRCT; hypertonic saline solution; ascitesHepatologymedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryGastroenterologyFurosemideAscitesMiddle Agedmedicine.diseaseHypertonic salineSurgeryTreatment OutcomeEffusionAnesthesiaFemaleDiureticmedicine.symptombusinessRCTmedicine.drugAlimentary pharmacologytherapeutics
researchProduct

Assessment of the cytotoxic potential of an aqueous-ethanolic extract from Thalassia testudinum angiosperm marine grown in the Caribbean Sea

2018

Abstract Objectives Reported antioxidant, anti-inflammatory and neuroprotective properties for one aqueous-ethanolic extract from Thalassia testudinum which grows in the Caribbean Sea compelled us to explore about extract cytotoxic effects. Methods Cell viability was assayed on tumour (HepG2, PC12, Caco-2 and 4T1) and non-tumour (VERO, 3T3, CHO, MCDK and BHK2) cell lines. The extract effects upon primary cultures of rat and human hepatocytes and human lymphocytes were assayed. Key findings The extract exhibited cytotoxicity against cancer cells compared to normal cells, and the IC50 values were 102 μg/ml for HepG2, 135 μg/ml for PC12, 165 μg/ml for Caco-2 and 129 μg/ml for 4T1 cells after 4…

AdultMale0301 basic medicineCell SurvivalDNA damagePrimary Cell CulturePharmaceutical ScienceHydrocharitaceaePC12 CellsRats Sprague-DawleyInhibitory Concentration 5003 medical and health sciencesNeoplasmsAnimalsHumansCytotoxic T cellLymphocytesViability assayCytotoxicityPharmacologyDose-Response Relationship DrugEthanolbiologyPlant ExtractsChemistryPharmacology. TherapyWaterHep G2 Cellsbiology.organism_classificationAntineoplastic Agents PhytogenicMolecular biologyRatsComet assay030104 developmental biologyCaribbean RegionCell cultureThalassia testudinumCancer cellSolventsCaco-2 CellsThalassia testudinum DNA damage cytotoxicity oxidative stressJournal of pharmacy and pharmacology
researchProduct

Metabolomic Changes after Coffee Consumption: New Paths on the Block

2021

Scope Several studies suggest that regular coffee consumption may help preventing chronic diseases, but the impact of daily intake and the contribution of coffee metabolites in disease prevention are still unclear. The present study aimed at evaluating whether and how different patterns of coffee intake (one cup of espresso coffee/day, three cups of espresso coffee/day, one cup of espresso coffee/day and two cocoa-based products containing coffee two times per day) might impact endogenous molecular pathways. Methods and results A three-arm, randomized, cross-over trial was performed in 21 healthy volunteers who consumed each treatment for one month. Urine samples were collected to perform u…

AdultMale0301 basic medicineEndocrinology Diabetes and MetabolismcoffeeEnergy metabolismMedicine (miscellaneous)030209 endocrinology & metabolismCoffee consumptionParallel computingUrine030204 cardiovascular system & hematologyBiology03 medical and health sciences0302 clinical medicineMetabolomicsArginine biosynthesisBlock (telecommunications)CaffeineCoffee intakeHumansxenobioticsFood scienceAmino AcidsMathematicsCacaoNutrition and Dietetics030109 nutrition & dieteticsDose-Response Relationship Drugmetabolomics3. Good healthMetabolic pathway030104 developmental biologycocoabiomarkerFemaleSteroidsDisease preventionCardiology and Cardiovascular Medicine[SDV.AEN]Life Sciences [q-bio]/Food and NutritionBiomarkersMetabolic Networks and PathwaysFood ScienceBiotechnology
researchProduct